26.45
price up icon0.94%   0.2349
 
loading
Precedente Chiudi:
$26.22
Aprire:
$26.26
Volume 24 ore:
798.51K
Relative Volume:
0.37
Capitalizzazione di mercato:
$11.65B
Reddito:
$2.24B
Utile/perdita netta:
$673.24M
Rapporto P/E:
235.15
EPS:
0.1125
Flusso di cassa netto:
$2.67B
1 W Prestazione:
+3.47%
1M Prestazione:
-4.62%
6M Prestazione:
-2.59%
1 anno Prestazione:
-1.97%
Intervallo 1D:
Value
$26.23
$26.52
Intervallo di 1 settimana:
Value
$25.10
$26.52
Portata 52W:
Value
$25.10
$31.66

Royalty Pharma Plc Stock (RPRX) Company Profile

Name
Nome
Royalty Pharma Plc
Name
Telefono
(212) 883-0200
Name
Indirizzo
110 EAST 59TH STREET, NEW YORK, NY
Name
Dipendente
89
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
RPRX's Discussions on Twitter

Confronta RPRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
RPRX 26.45 11.65B 2.24B 673.24M 2.67B 0.1125
VRTX 446.48 115.74B 10.63B -479.80M -1.35B 13.33
REGN 740.49 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.15 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.56 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.47 24.49B 3.30B -501.07M 1.03B 11.54

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-06-03 Downgrade UBS Buy → Neutral
2022-06-14 Ripresa UBS Buy
2022-05-13 Iniziato Scotiabank Sector Outperform
2022-04-27 Iniziato Goldman Buy
2022-04-14 Aggiornamento JP Morgan Neutral → Overweight
2022-04-06 Ripresa Morgan Stanley Overweight
2021-10-29 Aggiornamento Citigroup Neutral → Buy
2021-07-30 Iniziato Tigress Financial Buy
2020-11-09 Aggiornamento UBS Neutral → Buy
2020-07-14 Iniziato Evercore ISI In-line
2020-07-13 Iniziato BofA Securities Buy
2020-07-13 Iniziato Citigroup Neutral
2020-07-13 Iniziato Cowen Outperform
2020-07-13 Iniziato Goldman Neutral
2020-07-13 Iniziato JP Morgan Neutral
2020-07-13 Iniziato Morgan Stanley Equal-Weight
2020-07-13 Iniziato SunTrust Buy
2020-07-13 Iniziato UBS Neutral
Mostra tutto

Royalty Pharma Plc Borsa (RPRX) Ultime notizie

pulisher
Nov 19, 2024

Royalty Pharma (NASDAQ:RPRX) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Victory Capital Management Inc. Boosts Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 19, 2024
pulisher
Nov 17, 2024

Amalgamated Bank Sells 48,057 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 17, 2024
pulisher
Nov 16, 2024

Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy + - Seeking Alpha

Nov 16, 2024
pulisher
Nov 15, 2024

Royalty Pharma stock hits 52-week low at $25.2 amid market shifts - Investing.com India

Nov 15, 2024
pulisher
Nov 15, 2024

Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week LowTime to Sell? - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Simplify Asset Management Inc. Increases Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

(RPRX) Technical Data - Stock Traders Daily

Nov 14, 2024
pulisher
Nov 14, 2024

Royalty Pharma Announces Inaugural Prize for Impact in Healthcare - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

Royalty Pharma Awards Inaugural Healthcare Prize to Michael Milken for Cancer Research Impact | RPRX Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade - The Motley Fool

Nov 14, 2024
pulisher
Nov 13, 2024

Ex-Dividend Reminder: Cencora, Royalty Pharma and Brookline Bancorp - Nasdaq

Nov 13, 2024
pulisher
Nov 13, 2024

Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX) - Simply Wall St

Nov 13, 2024
pulisher
Nov 13, 2024

Royalty Pharma's (NASDAQ:RPRX) Profits May Not Reveal Underlying Issues - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

Syndax shares slide despite pivotal trial success - The Pharma Letter

Nov 13, 2024
pulisher
Nov 12, 2024

New South Capital Management Inc. Has $69.77 Million Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Baillie Gifford & Co. - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Los Angeles Capital Management LLC Lowers Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 12, 2024
pulisher
Nov 11, 2024

Van ECK Associates Corp Boosts Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 11, 2024
pulisher
Nov 10, 2024

Royalty Pharma Q3 2024 Earnings Preview - MSN

Nov 10, 2024
pulisher
Nov 10, 2024

Summit Global Investments Purchases New Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 10, 2024
pulisher
Nov 09, 2024

Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Executive Wealth Management LLC - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Royalty Pharma Stock: Massive Opportunity Ahead (NASDAQ:RPRX) - Seeking Alpha

Nov 09, 2024
pulisher
Nov 08, 2024

Morgan Stanley's Strategic Reduction in Royalty Pharma PLC Holdi - GuruFocus.com

Nov 08, 2024
pulisher
Nov 07, 2024

Royalty Pharma plc (NASDAQ:RPRX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 07, 2024
pulisher
Nov 07, 2024

Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Royalty Pharma plc (RPRX) to Acquire Royalty Interest in Geron’s (GERN) RYTELO for $125M - StreetInsider.com

Nov 07, 2024
pulisher
Nov 07, 2024

Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Robeco Institutional Asset Management B.V. - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Royalty Pharma PLC (RPRX) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic Acquisitions - Investing.com Canada

Nov 07, 2024
pulisher
Nov 07, 2024

Royalty Pharma PLC (RPRX): A Strategic SWOT Insight - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

Royalty Pharma Reports Strong Q3 2024 Results - TipRanks

Nov 07, 2024
pulisher
Nov 06, 2024

Compared to Estimates, Royalty Pharma (RPRX) Q3 Earnings: A Look at Key Metrics - Yahoo Finance

Nov 06, 2024
pulisher
Nov 06, 2024

Earnings call: Royalty Pharma reports robust Q3 growth, raises guidance By Investing.com - Investing.com Nigeria

Nov 06, 2024
pulisher
Nov 06, 2024

Royalty Pharma reports robust Q3 growth, raises guidance By Investing.com - ழ தொலைக்காட்சி

Nov 06, 2024
pulisher
Nov 06, 2024

Earnings call: Royalty Pharma reports robust Q3 growth, raises guidance - Investing.com

Nov 06, 2024
pulisher
Nov 06, 2024

Royalty Pharma Reports Third Quarter 2024 Results - ForexTV.com

Nov 06, 2024
pulisher
Nov 06, 2024

Royalty Pharma plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 06, 2024
pulisher
Nov 06, 2024

Royalty Pharma Q3 Soars: 15% Revenue Growth, $1.2B Deployment Drives Guidance Boost | RPRX Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 06, 2024

Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail

Nov 06, 2024
pulisher
Nov 06, 2024

River Road Asset Management LLC Has $13.30 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Citeline News & Insights

Nov 05, 2024
pulisher
Nov 05, 2024

Insights Ahead: Royalty Pharma's Quarterly Earnings - Benzinga

Nov 05, 2024
pulisher
Nov 05, 2024

Royalty Pharma (NASDAQ:RPRX) Raised to “Buy” at StockNews.com - Defense World

Nov 05, 2024
pulisher
Nov 05, 2024

Syndax agrees funding with Royalty Pharma for Niktimvo US sales - Yahoo Finance

Nov 05, 2024
pulisher
Nov 05, 2024

Royalty Pharma plc and Syndax Pharmaceuticals Enter into $350 Million Royalty Funding Agreement for Niktimvo - Marketscreener.com

Nov 05, 2024
pulisher
Nov 05, 2024

Royalty Pharma (NASDAQ:RPRX) Upgraded at StockNews.com - MarketBeat

Nov 05, 2024
pulisher
Nov 04, 2024

Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo - The Manila Times

Nov 04, 2024
pulisher
Nov 04, 2024

Syndax secures $350 million in royalty funding from Royalty Pharma By Investing.com - Investing.com UK

Nov 04, 2024
pulisher
Nov 04, 2024

Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™ - StockTitan

Nov 04, 2024
pulisher
Nov 04, 2024

With 72% ownership, Royalty Pharma plc (NASDAQ:RPRX) boasts of strong institutional backing - Simply Wall St

Nov 04, 2024

Royalty Pharma Plc Azioni (RPRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Royalty Pharma Plc Azioni (RPRX) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
RIGGS RORY B
Director
Jan 03 '24
Sale
27.79
199,098
5,532,276
55,801
RIGGS RORY B
Director
Jan 04 '24
Sale
27.55
35,702
983,504
20,099
Avara Management Ltd
10% Owner
Dec 29 '23
Sale
28.04
65,803
1,845,406
2,477,520
Avara Management Ltd
10% Owner
Dec 28 '23
Sale
28.20
209,863
5,918,934
2,543,323
Avara Management Ltd
10% Owner
Dec 27 '23
Sale
28.01
41,729
1,168,754
2,753,186
Avara Management Ltd
10% Owner
Dec 15 '23
Sale
28.01
10,229
286,499
2,794,915
Avara Management Ltd
10% Owner
Dec 14 '23
Sale
28.91
364,441
10,534,276
2,805,144
Avara Management Ltd
10% Owner
Dec 13 '23
Sale
28.95
307,935
8,916,012
3,169,585
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):